Translational Core
Translational Core
批准号:
10569664
负责人:
Markos Leggas
金额:
$25.01万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-03-01 至 2025-01-31
关键词:
AccelerationAddressAdhesionsAnimalsBasic ScienceBiological AssayBiologyBiomedical ResearchCenters of Research ExcellenceChemicalsClinicalClinical ResearchCollectionComplementConsultationsData AnalysesDedicationsDevelopmentDevicesDiseaseDoctor of PhilosophyDrug KineticsExcretory functionFacultyGoalsHealthIn VitroInfrastructureKentuckyLeadLeadershipLibrariesMentorsMentorshipMetabolismMethodsMicrobial BiofilmsModelingMolecular MedicineNatural ProductsOrganic SynthesisPharmacologic SubstanceReporterResearchResearch DesignResearch PersonnelResearch SupportResourcesScienceScientistServicesToxic effectTranslational ResearchType IV Secretion System PathwayUniversitiesValidationabsorptionantimicrobialcareer developmentclinical applicationcytotoxicitydesignexperimental studyfaculty researchimmunoregulationinnovationinstrumentationmultidisciplinarypre-clinicalpreventprimary outcomeresearch facultyscreeningscreening servicesstemsynergismtooltranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT – TRANSLATIONAL CORE
We propose to establish a Center of Biomedical Research Excellence (COBRE) in Pharmaceutical Research
and Innovation at the University of Kentucky (UK). CPRI will serve as a comprehensive multidisciplinary center
focused on translational chemical biology [the nexus of chemical biology (the application of chemical biology
principles to develop validated probe/models to advance our understanding of biology) and pharmaceutical
science (the application of pharmaceutical principles to advance leads/materials/devices that address unmet
clinical needs)]. The COBRE will leverage and develop unique translational chemical biology research support
infrastructure/expertise to facilitate junior faculty mentorship and career development, innovative biomedical
research probe/tool/model/materials development and validation, and the early advancement of potential
‘translatable’ assets. Within this context, the CPRI Translational Core will provide key infrastructure and expertise
to support experimental studies central to probe/lead/materials discovery. Under the co-direction of Drs. Markos
Leggas and Jon Thorson, the Core will support assay design, development, validation and implementation; pilot
screening campaigns; a suite of in vitro absorption, distribution, metabolism, excretion and toxicity (ADMET)
assays; and first in animal ADMET/pharmacokinetics (PK) studies. Support in the Core will be tailored toward
specific COBRE project/pilot needs and screening services will also leverage CPRI-exclusive compound
collections (both natural products and synthetics). The Core’s services have been strategically designed to
integrate with, and complement, the support provided by the CPRI Computational Core and the CPRI-affiliated
COBRE for Molecular Medicine Organic Synthesis Core. Together, CPRI’s corresponding fully integrated
research support capabilities and expertise will accelerate innovative, ‘translatable’ transdisciplinary research
and facilitate junior investigator career development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Translational Core
-
批准号:10112942
-
项目类别:
-
资助金额:$25.7万
-
财政年份:2020
-
负责人:Markos Leggas
-
依托单位:
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma
-
批准号:10166806
-
项目类别:
-
资助金额:$61.72万
-
财政年份:2020
-
负责人:Markos Leggas
-
依托单位:
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma
-
批准号:10412967
-
项目类别:
-
资助金额:$59.23万
-
财政年份:2020
-
负责人:Markos Leggas
-
依托单位:
Translational Core
-
批准号:10333387
-
项目类别:
-
资助金额:$27.92万
-
财政年份:2020
-
负责人:Markos Leggas
-
依托单位:
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma
-
批准号:10654595
-
项目类别:
-
资助金额:$57.98万
-
财政年份:2020
-
负责人:Markos Leggas
-
依托单位:
Phase I and Biological Studies of DB67 - A Blood Stable Camptothecin
-
批准号:7344745
-
项目类别:
-
资助金额:$20.51万
-
财政年份:2007
-
负责人:Markos Leggas
-
依托单位:
Phase I and Biological Studies of DB67 - A Blood Stable Camptothecin
-
批准号:7224428
-
项目类别:
-
资助金额:$20.51万
-
财政年份:2007
-
负责人:Markos Leggas
-
依托单位:
海外基金